Clinical trials · New York, NY
Cancer clinical trials in New York
We’re tracking 1,363 recruiting cancer studies with a site in or near New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05751434RecruitingPhase 2
Exercise therapy for prostate cancer patients on active surveillance
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
New York, New YorkAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
New York, New YorkAges 18 years+ - NCT06596694RecruitingPhase 1/Phase 2
Patritumab deruxtecan for advanced gastrointestinal cancers
This trial tests a new drug (patritumab deruxtecan) for people with advanced or spreading cancers of the digestive system (including colorectal, bile duct, liver, and stomach/esophageal cancers). The goal is to see if it can shrink tumors or stop them from growing.
New York, New YorkAges 18 years+ - NCT06205485RecruitingPhase 3
Chemotherapy and surgery vs chemoradiation for rectal cancer
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
New York, New YorkAges 18 years+ - NCT07493304RecruitingPhase 3
Preventing blood clots in people with cancer
This trial tests a new anticoagulant medication to treat and prevent blood clots in patients with active cancer. You may qualify if you have a recent clot in your leg or lungs and are already taking a blood thinner.
New York, New YorkAges 18 years+ - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
New York, New YorkAges 18 years+ - NCT06370143Recruiting
Health information study to understand and prevent stomach cancer
This study collects health information from people at different stages of stomach cancer risk, including those with precancerous changes, healthy individuals, and those with early stomach cancer. The goal is to better understand and prevent stomach cancer.
New York, New YorkAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
New York, New YorkAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+ - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
New York, New YorkAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06626243Recruiting
Comparing surgery types for lung cancer after pre-surgery therapy
This trial compares different surgical methods (robotic, VATS, or open surgery) used to remove lung cancer after patients have had chemotherapy and/or immunotherapy before their operation. It looks at results from five specialized hospitals to help understand which approach may work best.
New York, New YorkAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
New York, New YorkAges 18 years+ - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
New York, New YorkAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
New York, New YorkAges 8 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
New York, New YorkAges 18 years+ - NCT07203482Recruiting
HIFU ablation treatment for prostate cancer outcomes
This study collects data on men with early, low-risk prostate cancer who choose to have a targeted ultrasound treatment called HIFU (High-Intensity Focused Ultrasound). It looks at how well this treatment works and how men recover.
New York, New YorkAges 40–95 - NCT05207098Recruiting
Brain testing and questionnaires during head and neck radiation
This study checks how people’s thinking and brain functioning change while they are getting radiation therapy for head and neck cancer. It uses simple computer tests and questionnaires to better understand who may be at risk for trouble thinking during treatment.
New York, New YorkAges 18–89 - NCT06689176Recruiting
Chlorhexidine wash during bladder removal surgery
This trial tests a special antibacterial wash (chlorhexidine) applied to a piece of intestine used to create a new way for urine to leave the body after bladder removal. It aims to reduce infections and improve recovery.
New York, New YorkAges 18 years+ - NCT06637462Recruiting
Studying standard treatment response before rectal cancer surgery
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
New York, New YorkAges 18 years+ - NCT06462183RecruitingPhase 1
Study of RGT-61159 for Advanced ACC or CRC
This trial tests a new drug called RGT-61159 for adults with adenoid cystic carcinoma or colorectal cancer that has returned or stopped responding to treatment. The goal is to see if the drug is safe and effective in shrinking tumors.
New York, New YorkAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
New York, New YorkAges 18 years+
Hear when a new Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 13 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Commack · 6 studies
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Westchester · 6 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
- NYU Langone Health · 5 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in New York.
Common questions
- Are there cancer clinical trials near New York?
- Yes. We're currently tracking 1,363 recruiting cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.